M6P Therapeutics is a privately held, venture-backed life sciences company developing first-in-class, next-generation, targeted recombinant enzyme and gene therapies for lysosomal storage disorders (LSDs) by unlocking the potential of mannose 6-phosphate (M6P).Lysosomal storage disorders (LSDs) are a family of approximately 50 rare, genetic, and life-threatening diseases characterized by a deficiency in a specific lysosomal enzyme.
M6P Therapeutics have successfully generated a technology platform for developing next generation enzyme replacement and Gene Therapy to treat and/or cure lysosomal storage disorders. Their scientists are working to develop life-changing therapies as quickly and efficiently as possible to meet the urgent needs of individuals living with these serious, rare LSDs.
M6P Therapeutics chose to work with Dotmatics in 2021 to further streamline their research workflows with ELN, Bioregister and lab data automation using BioBright DarwinSync.
“The Dotmatics group invested in our patient first company vision immediately and we understood that our collaboration would immediately yield better science and discovery.”
Michael DiGruccio, M6P Therapeutics